OncoMatch

OncoMatch/Clinical Trials/NCT06356714

Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status

Is NCT06356714 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for colorectal cancer.

Phase 2RecruitingSun JingNCT06356714Data as of Jun 2026Location: China

Treatment: Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line RegimensEvaluate the efficacy and safety of Nocardia rubra cell wall skeleton in combination with prior second- or third-line regimens for the treatment of potentially hazardous colorectal cancer SD(Stable Disease) status in the real world.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens

Cancer type

Colorectal Cancer

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 1 prior line

Must have received: — second- or third-line therapy for advanced or metastatic colorectal cancer

Prior second- or third-line therapy for advanced or metastatic colorectal cancer

Lab requirements

Blood counts

absolute neutrophil count ≥ 1.5 x 10^9/L; hemoglobin ≥ 9.0 g/dl; platelet count ≥ 100 x 10^9/L

Kidney function

serum creatinine ≤ 1.5 x ULN

Liver function

total bilirubin ≤ 1.5 x ULN; gammaglutaminase and alkaline phosphatase ≤ 3 x ULN (≤ 5 x ULN for patients with hepatic/liver metastases)

absolute neutrophil count ≥ 1.5 x 10^9 /L; hemoglobin ≥ 9.0 g/dl; platelet count ≥ 100 x 10^9 /L; total bilirubin ≤ 1.5 x ULN; gammaglutaminase and alkaline phosphatase ≤ 3 x ULN (≤ 5 x ULN for patients with hepatic/liver metastases); serum creatinine ≤ 1.5 x ULN

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06356714 currently recruiting?

Yes, this trial is currently recruiting patients.

Is prior treatment required for enrollment?

Yes. Patients must have previously received .

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify